| Literature DB >> 27128939 |
Ilenia Siciliano1, Davide Spadaro2,3, Ambra Prelle4, Dario Vallauri5, Maria Chiara Cavallero6, Angelo Garibaldi7, Maria Lodovica Gullino8,9.
Abstract
Aflatoxins, produced by Aspergillus flavus and A. parasiticus, can contaminate different foodstuffs, such as nuts. Cold atmospheric pressure plasma has the potential to be used for mycotoxin detoxification. In this study, the operating parameters of cold atmospheric pressure plasma were optimized to reduce the presence of aflatoxins on dehulled hazelnuts. First, the effect of different gases was tested (N₂, 0.1% O₂ and 1% O₂, 21% O₂), then power (400, 700, 1000, 1150 W) and exposure time (1, 2, 4, and 12 min) were optimized. In preliminary tests on aflatoxin standard solutions, this method allowed to obtain a complete detoxification using a high power for a few minutes. On hazelnuts, in similar conditions (1000 W, 12 min), a reduction in the concentration of total aflatoxins and AFB₁ of over 70% was obtained. Aflatoxins B₁ and G₁ were more sensitive to plasma treatments compared to aflatoxins B₂ and G₂, respectively. Under plasma treatment, aflatoxin B₁ was more sensitive compared to aflatoxin G₁. At the highest power, and for the longest time, the maximum temperature increment was 28.9 °C. Cold atmospheric plasma has the potential to be a promising method for aflatoxin detoxification on food, because it is effective and it could help to maintain the organoleptic characteristics.Entities:
Keywords: aflatoxins; cold atmospheric pressure plasma; detoxification; hazelnut; nitrogen; nuts; temperature; time
Mesh:
Substances:
Year: 2016 PMID: 27128939 PMCID: PMC4885040 DOI: 10.3390/toxins8050125
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Structures of the four aflatoxins. AFB1 (1); AFB2 (2); AFG1 (3) and AFG2 (4).
Residual (%) aflatoxin B1 and total aflatoxins on aqueous standard solutions after treatments with atmospheric plasma generated with different gas mixtures and applied for different exposure times (Power = 1000 W).
| Plasma | AFB1 (%) | Afs 1 (%) | ||||
|---|---|---|---|---|---|---|
| gas | 1 min | 2 min | 4 min | 1 min | 2 min | 4 min |
| 21% O2 | 100 | 100 | 100 | 99.44 | 95.50 | 94.9 |
| 1% O2 | 100 | 50.2 ± 17.1 | 0.50 ± 0.29 | 100 | 88.5 ± 7.55 | 50.5 ± 14.0 |
| 0.1% O2 | 78.1 ± 0.07 | 31.3 ± 5.98 | 9.31 ± 0.27 | 92.3 ± 2.89 | 73.8 ± 8.49 | 59.7 ± 1.49 |
| N2 | 87.5 ± 17.4 | 20.0 ± 0.69 | 0 | 77.9 ± 11.1 | 32.8 ± 4.72 | 13.7 ± 0.19 |
1 average residual concentration of AFB1, AFB2, AFG1, and AFG2, after plasma treatment.
Residual (%) aflatoxin B1 and total aflatoxins on aqueous standard solutions and on contaminated hazelnuts after treatments with atmospheric plasma generated with different powers and applied for different exposure times.
| Power (W) | Time (min) | Standards | Hazelnuts 1 | ||
|---|---|---|---|---|---|
| AFB1 (%) | AFs 2 (%) | AFB1 (%) | AFs 2 (%) | ||
| 400 | 1 | 25.4 ± 6.13 | 57.1 ± 28.8 | 100 ± 1.60 | 97.7 ± 13.6 |
| 2 | 7.75 ± 0.17 | 20.6 ± 14.6 | 100 ± 5.10 | 98.7 ± 23.9 | |
| 4 | 4.49 ± 0.80 | 9.40 ± 6.41 | 83.2 ± 27.5 | 81.2 ± 30.0 | |
| 12 | 0 | 0 | 54.3 ± 0.91 | 54.1 ± 6.01 | |
| 700 | 1 | 12.7 ± 6.08 | 44.3 ± 25.6 | 99.6 ± 68.6 | 90.9 ± 41.6 |
| 2 | 0 | 6.61 ± 1.94 | 84.7 ± 15.2 | 84.7 ± 10.2 | |
| 4 | 0 | 2.40 | 83.1 ± 6.81 | 83.9 ± 30.2 | |
| 12 | 0 | 0 | 44.8 ± 3.36 | 52.9 ± 10.7 | |
| 1000 | 1 | 9.52 ± 4.70 | 24.0 ± 12.1 | 96.2 ± 6.50 | 88.5 ± 12.9 |
| 2 | 0 | 0.60 | 82.5 ± 30.2 | 79.9 ± 34.8 | |
| 4 | 0 | 0 | 78.5 ± 10.7 | 66.9 ± 11.8 | |
| 12 | 0 | 0 | 35.7 ± 0.87 | 25.8 ± 13.2 | |
| 1150 | 1 | 0 | 0 | 85.2 ± 8.46 | 81.7 ± 20.3 |
| 2 | 0 | 0 | 60.2 ± 3.31 | 62.0 ± 13.4 | |
| 4 | − | − | 50.6 ± 9.77 | 60.0 ± 20.8 | |
| 12 | − | − | 29.1 ± 5.89 | 30.4 ± 9.04 | |
1 Mean Initial concentrations of AFB1, and AFs where 8.02 ng/g and 36.11 ng/g respectively; 2 Average residual concentration of AFB1, AFB2, AFG1, and AFG2, after plasma treatment.
Figure 2Residue of AFB1, AFB2, AFG1 and AFG2 after a treatment at 400 W on standard solutions.
Figure 3Increase in temperature (∆T °C) during treatments.
Figure 4Schematic diagram of the plasma system used in this work for treatments.